Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new late-breaking data highlighting the clinical and economic ...

But according to wellness expert and Dietium.com founder Srasti, our collective reliance on this single number is “not just ...

Anavex (AVXL) awaits a key EU ruling on its Alzheimer’s drug. Learn about trial challenges, approval risks, and why a Sell ...

U.S. President Donald Trump's embrace of an old generic drug called leucovorin for use against a rare disorder that causes ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data ...

The Phase 3 ADAPT SERON study met its primary endpoint (p-value=0.0068), demonstrating that AChR-Ab seronegative gMG patients treated with VYVGART achieved a statistically significant improvement in ...

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

A global analysis of 125 turmeric supplements across five major markets revealed widespread inconsistencies in labeling, ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...

Cystic fibrosis (CF) therapeutics refer to treatments designed to manage and alleviate the symptoms of cystic fibrosis, a ...

According to the latest analysis by DataM Intelligence, the Next-Generation Multiple Myeloma Therapies Market Size was valued ...